SE8801275L - New uses of dopamine agonists - Google Patents

New uses of dopamine agonists

Info

Publication number
SE8801275L
SE8801275L SE8801275A SE8801275A SE8801275L SE 8801275 L SE8801275 L SE 8801275L SE 8801275 A SE8801275 A SE 8801275A SE 8801275 A SE8801275 A SE 8801275A SE 8801275 L SE8801275 L SE 8801275L
Authority
SE
Sweden
Prior art keywords
dopamine agonists
new uses
dopamine
schizophrenia
anxiety
Prior art date
Application number
SE8801275A
Other languages
English (en)
Swedish (sv)
Other versions
SE8801275A0 (sv
SE8801275D0 (sv
Inventor
R Markstein
J Palacios
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB878708626A external-priority patent/GB8708626D0/en
Priority claimed from GB878708898A external-priority patent/GB8708898D0/en
Priority claimed from GB878710062A external-priority patent/GB8710062D0/en
Priority claimed from GB878720366A external-priority patent/GB8720366D0/en
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of SE8801275D0 publication Critical patent/SE8801275D0/xx
Publication of SE8801275A0 publication Critical patent/SE8801275A0/sv
Publication of SE8801275L publication Critical patent/SE8801275L/

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, ***e
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SE8801275A 1987-04-10 1988-04-08 New uses of dopamine agonists SE8801275L (sv)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB878708626A GB8708626D0 (en) 1987-04-10 1987-04-10 Indolophenanthridines
GB878708898A GB8708898D0 (en) 1987-04-14 1987-04-14 Indolophenanthridines
GB878710062A GB8710062D0 (en) 1987-04-28 1987-04-28 Indolophenanthridines
GB878720366A GB8720366D0 (en) 1987-08-28 1987-08-28 Dopamine d1 receptor agonists

Publications (3)

Publication Number Publication Date
SE8801275D0 SE8801275D0 (sv) 1988-04-08
SE8801275A0 SE8801275A0 (sv) 1988-10-19
SE8801275L true SE8801275L (sv) 1988-10-19

Family

ID=27449909

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8801275A SE8801275L (sv) 1987-04-10 1988-04-08 New uses of dopamine agonists

Country Status (11)

Country Link
US (1) US4855306A ( )
JP (1) JPS63258819A ( )
KR (1) KR880012227A ( )
AU (1) AU1440088A ( )
DE (1) DE3811274A1 ( )
DK (1) DK193588A ( )
FR (1) FR2613623A1 ( )
GB (1) GB2205495A ( )
IT (1) IT1219906B ( )
NL (1) NL8800823A ( )
SE (1) SE8801275L ( )

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69838789T2 (de) * 1997-03-12 2008-10-30 Suzanne Cambridge de la Monte Verfahren zur behandlung oder prävention der alzheimerischen krankheit
US20040058873A1 (en) * 1998-03-12 2004-03-25 Esmond Robert W. Method for treating or preventing Alzheimer's disease
US6362371B1 (en) * 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
DE10148233A1 (de) * 2001-09-28 2003-04-10 Boehringer Ingelheim Pharma Verbindungen zur Reduzierung übermäßiger Nahrungsaufnahme
EP3173082A1 (en) * 2002-05-17 2017-05-31 Duke University Method for treating obesity
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
DE10312809A1 (de) * 2003-03-21 2004-09-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pramipexol zur Reduzierung übermäßiger Nahrungsaufnahme bei Kindern
US20040266794A1 (en) * 2003-03-21 2004-12-30 Boehringer Ingelheim International Gmbh Pramipexole for the reduction of excessive food intake for children
CN1784221B (zh) 2003-04-29 2010-07-07 奥雷西根治疗公司 影响体重减轻的组合物
EP1626703A2 (en) * 2003-05-22 2006-02-22 Yeda Research And Development Co. Ltd. Dopamine and agonists and antagonists thereof for modulation of suppressive activity of cd4+cd25+ regulatory t cells
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
CA2553207A1 (en) * 2004-01-13 2005-08-04 Kishore M. Gadde Compositions of an anticonvulsant and an antipsychotic drug for affecting weight loss
WO2005110405A1 (en) * 2004-05-03 2005-11-24 Duke University Compositions for affecting weight loss
US20080306019A1 (en) * 2005-05-03 2008-12-11 Booze Rosemarie M Dopamine Receptor Agonists in the Treatment and Prevention of Hiv-Induced Dementia
EP2135603B1 (en) 2005-11-22 2013-01-02 Orexigen Therapeutics, Inc. Compositions and methods for increasing insulin sensitivity
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
WO2008060964A2 (en) 2006-11-09 2008-05-22 Orexigen Therapeutics, Inc. Unit dosage package and methods for administering weight loss medications
KR101971218B1 (ko) 2006-11-09 2019-08-27 오렉시젠 세러퓨틱스 인크. 신속하게 용해되는 중간층을 포함하는 층상의 약제학적 제형
EP2303025A4 (en) 2008-05-30 2012-07-04 Orexigen Therapeutics Inc METHOD FOR TREATING DIGITAL FAT SWITCHES
EP2379607B1 (en) * 2009-08-27 2013-12-04 Daikin Industries, Ltd. Processing additive, molding composition, masterbatch of processing additive and molding article
AU2011203867B2 (en) 2010-01-11 2015-12-03 Nalpropion Pharmaceuticals Llc Methods of providing weight loss therapy in patients with major depression
EA201492175A1 (ru) 2012-06-06 2015-10-30 Орексиджен Терапьютикс, Инк. Способы лечения избыточного веса и ожирения

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3402392A1 (de) * 1984-01-25 1985-08-01 Sandoz-Patent-GmbH, 7850 Lörrach Neue ergolinderivate, deren herstellung und deren verwendung

Also Published As

Publication number Publication date
SE8801275A0 (sv) 1988-10-19
KR880012227A (ko) 1988-11-26
US4855306A (en) 1989-08-08
DK193588D0 (da) 1988-04-08
AU1440088A (en) 1988-10-13
DE3811274A1 (de) 1988-10-27
SE8801275D0 (sv) 1988-04-08
IT8847814A0 (it) 1988-04-05
GB2205495A (en) 1988-12-14
FR2613623A1 (fr) 1988-10-14
GB8808125D0 (en) 1988-05-11
DK193588A (da) 1988-10-11
NL8800823A (nl) 1988-11-01
JPS63258819A (ja) 1988-10-26
IT1219906B (it) 1990-05-24

Similar Documents

Publication Publication Date Title
SE8801275D0 (sv) New uses of dopamine agonists
PT804196E (pt) Utilizacao de antagonistas de serotonina (5ht3) para o tratamento de fibromialgia
EP0438230A3 (en) Indole-substituted five-membered heteroaromatic compounds
SE8203966L (sv) Kirurgiskt instrument for utforande av anastomos med hjelp av ringformiga festelement samt festelement for utforande av anastomos
IL98163A0 (en) Isoxazole-4-carboxamides and hydroxyalkylidene-cyanoacetamides,pharmaceuticals containing these compounds and their use
DE69110309D1 (de) Vorrichtung zur Erkennung einer baldigen Erschöpfung des Tintenvorrates.
DK182786A (da) Ikke-lagdelt toerformet absorberende produkt og fremgangsmaade til fremstilling af produktet
NO960630D0 (no) Heterocykler anvendelige som neurokinin antagonister
ES529312A0 (es) Procedimiento para la preparacion de 3-(1-sustituido-4-piperidil)-1, 2-bencisoxazoles
YU43809B (en) Process for obtaining new substituted benzamides
DK83789A (da) Substituerede 1,2,4-triazindioner, fremgangsmaader og mellemprodukter til deres fremstilling samt deres anvendelse
ES524439A0 (es) Procedimiento de obtencion de los 2-amino 5- (aralcoil piperidino alcoil) amino 1,4-diazoles
DE58904033D1 (de) Isoliereinrichtung zum optischen isolieren integrierter komponenten.
ES2039211T3 (es) Nuevos n-glicosilamidoderivados, procedimientos para su obtencion y su empleo como medicamentos.
DE58906414D1 (de) Vorrichtung zur Begrenzung des Eingangsstromes eines Speisegerätes.
DE59003199D1 (de) Vorrichtung zur Aufnahme von Notschlüsseln.
DE59000366D1 (de) Vorrichtung zum regeln des betriebs von hydromotoren.
FI890864A (fi) Anvaendning av 1,4-dihydropyridinderivat.
SU855196A1 (ru) Устройство дл перекрыти скважины
ES2040362T3 (es) Procedimiento para la preparacion de 2-(benzhidrilsulfonil)acetamida.
ES1012648U (es) Agarradero para baneras.
IT8985508A0 (it) Dispositivo per allargare pelli o simili.
SE8902700D0 (sv) Stoedkrage
ATE79937T1 (de) Vorrichtung zum absperren von rohrleitungen.
ES294121Y (es) Dispositivo de pedal para el accionamiento de valvulas de grifos

Legal Events

Date Code Title Description
NAV Patent application has lapsed

Ref document number: 8801275-2

Effective date: 19911101

Format of ref document f/p: F